R&D Centers

R&D Center in China

Key R&D Capabilities

Long-acting and Extended Release Technology

Liposome and Targeted Drug Delivery Technology

Biological Antibody Technology

PHM-TPD Platform

Innovative Medical Technology

R&D Center in the U.S.

Key R&D Capabilities

International R&D Collaboration

Exploratory Study for Innovative Drugs

Innovative Medical Technology

 

R&D Center in Europe

Key R&D Capabilities

Transdermal Drug Delivery Technology

Granted Patents

235 patents granted in China

and another 74 applications in progress.

595 patents granted overseas

while 119 applications in progress.

(As of June 2021)

Platforms and Technologies

Novel Drug Delivery Systems & PHM-TPD

Novel Drug Delivery Systems:

Long-acting and extended release technology,

Liposome and targeted drug delivery technology,

Transdermal drug delivery technology;

Novel Drug Delivery Systems & PHM-TPD

PHM-TPD platform:

PHM-TPD platform based on targeted protein degradation; key procedure establishment for targets discovery, drug design and synthesis, biological screening and evaluation;

Antibodies

Human Antibody Transgenic Mouse and Phage Display Technology Platform:

Significant improvement of efficiency and speed in antibody development, effective screening of antibody candidates;

Antibodies

Bispecific T-cell Engager Technology Platform:

High affinity binding to tumor targets (better efficacy), low affinity binding to T-cells (lower toxicity), a wider therapeutic window;

Antibodies

Antibody Drug Conjugate Technology Platform:

Efficient screening of high-quality antibodies for ADC(Antibody Drug Conjugate);

Innovative Therapies

Nucleic Acid Therapy and Gene Therapy :

Research and development of novel therapies including AAV-based gene therapy and nucleic acid therapy (mRNA and Oligo). Both harbor significant potential to address a wide spectrum of diseases;

Innovative Therapies

Gene and Nucleic Acid Targeted Delivery:

Delivery is a critical enabling element in nucleic and gene therapy. The proprietary LNP platform adds value to the pipeline by enabling tissue and organ specific delivery;

Innovative Therapies

CAR-T Cell Immunotherapy:

Developed next-generation cell therapy technologies engineered to target neo-tumor antigens and accomplish other therapeutic functions. Novel non viral vector technology to enhance manufacturing efficiency. Improve cancer treatment by providing a personalized therapy option;

R&D Pipelines

Key Laboratory

The Laboratory of Long-acting and Targeting Drug Delivery System, focusing on the research of:

Long-acting drug delivery system and drug release technology

Targeting drug delivery system and drug release technology

High-end carrier materials for long-acting and targeting drug delivery

R&D Centers

located in China, the United States
and Europe

Robust R&D pipelines of drug candidates:

30+ in China

10+ overseas

Nearly
900 R&D professionals

R&D Centers

R&D Center in the U.S.

Key R&D Capabilities

Exploratory Study for Innovative Drugs

International R&D Collaboration

Innovative Medical Technology

R&D Center in China

Key R&D Capabilities

Long-acting and Extended Release Technology

Liposome and Targeted Drug Delivery Technology

Biological Antibody Technology

PHM-TPD  Platform

Innovative Medical Technology

R&D Center in Europe

Key R&D Capabilities

Transdermal Drug Delivery Technology

Granted Patents

235 patents granted in China

and another 74 applications in progress.

595 patents granted overseas

while 119 applications in progress.

(As of June 2021)

Platforms and Technologies

Novel Drug Delivery Systems & PHM-TPD

Novel Drug Delivery Systems:

Long-acting and extended release technology,

Liposome and targeted drug delivery technology,

Transdermal drug delivery technology;

Novel Drug Delivery Systems & PHM-TPD

PHM-TPD platform:

PHM-TPD platform based on targeted protein degradation; key procedure establishment for targets discovery, drug design and synthesis, biological screening and evaluation;

Antibodies

Human Antibody Transgenic Mouse and Phage Display Technology Platform:

Significant improvement of efficiency and speed in antibody development, effective screening of antibody candidates;

Antibodies

Bispecific T-cell Engager Technology Platform:

High affinity binding to tumor targets (better efficacy), low affinity binding to T-cells (lower toxicity), a wider therapeutic window;

Antibodies

Antibody Drug Conjugate Technology Platform:

Efficient screening of high-quality antibodies for ADC(Antibody Drug Conjugate);

Innovative Therapies

Nucleic Acid Therapy and Gene Therapy :

Research and development of novel therapies including AAV-based gene therapy and nucleic acid therapy (mRNA and Oligo). Both harbor significant potential to address a wide spectrum of diseases;

Innovative Therapies

Gene and Nucleic Acid Targeted Delivery:

Delivery is a critical enabling element in nucleic and gene therapy. The proprietary LNP platform adds value to the pipeline by enabling tissue and organ specific delivery;

Innovative Therapies

CAR-T Cell Immunotherapy:

Developed next-generation cell therapy technologies engineered to target neo-tumor antigens and accomplish other therapeutic functions. Novel non viral vector technology to enhance manufacturing efficiency. Improve cancer treatment by providing a personalized therapy option;

R&D Pipelines

Overseas R&D Pipelines
R&D Pipelines in China

Key Laboratory

The Laboratory of Long-acting and Targeting Drug Delivery System, focusing on the research of:

Long-acting drug delivery system and drug release technology

Targeting drug delivery system and drug release technology

High-end carrier materials for long-acting and targeting drug delivery